Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Complete title: A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody in Combination with Sargramostim in Patients with Recurrent Osteosarcoma

Research Study Number AOST1421
 
Principal Investigator Doug Hawkins, MD
 
Phase II

Research Study Description

This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent). Dinutuximab is a type of drug called a monoclonal antibody. It is designed to recognize a specific target on the surface of cancer cells. It then attaches to the cancer cells and kills them, without harming normal cells. Sargramostim may help the body increase the amount of white blood cells it produces, which help the body fight off infections. Giving sargramostim with dinutuximab may help the dinutuximab work better and kill more cancer cells.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number AOST1421
 
Contact Alvin Ongoco
 
E-mail
 

Keywords: Lung Cancer; Pediatric Cancers, Miscellaneous; Sarcoma; Solid Tumors; Neoplasms; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Bone Tissue

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials